Takeda, Affymax Start Phase-3 Trials for Anemia Drug (Japan)
This article was originally published in PharmAsia News
Executive Summary
Phase 3 clinical trials have commenced for Hematide, an anemia drug produced by Takeda Pharmaceutical Co. and Affymax Inc. The clinical trials will gauge the effectiveness of the drug in approximately 2,200 patients with chronic renal failure. The companies hope the drug will win approval in the United States and Europe by the end of the decade. (Click here for more - May Require Paid Subscription